Share
Roopal Thakkar
“Dr. Thakkar brings a physician’s insight, a deep commitment to innovation, and a proven track record in advancing clinical programs and building new capabilities,” said Rob Michael, Chief Executive Officer of AbbVie. “His experience in forging strategic partnerships and accelerating the delivery of medicines will be invaluable as he leads our R&D efforts and builds momentum across our diverse pipeline.”
“I am thrilled to take on these expanded responsibilities within AbbVie's R&D organization,” said Dr. Thakkar. “With over 90 drug and device programs in our pipeline, we have a tremendous opportunity to drive AbbVie’s growth and address significant health challenges. I look forward to leading our exceptional R&D team in delivering critical innovations for patients.”
Dr. Thomas J. Hudson, M.D., who currently serves as Senior Vice President and Chief Scientific Officer, Global Research, will retire from AbbVie. Since joining the company in 2016, Dr. Hudson has played a key role in shaping AbbVie's approach to early-stage science, building precision medicine capabilities, and developing strategic data initiatives to enhance drug discovery and development.
